{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T10:29:55Z","timestamp":1791973795412,"version":"4.4.0"},"reference-count":26,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2023,9,20]],"date-time":"2023-09-20T00:00:00Z","timestamp":1695168000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Ther Apher Dial"],"published-print":{"date-parts":[[2024,2]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Objectives<\/jats:title><jats:p>The aim of the study was to investigate the serological factors in predicting symptom improvement in myasthenia gravis (MG) patients who underwent plasmapheresis (PP).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>The relationship between symptom improvement and change in immunoglobin G (IgG) and acetylcholine receptor antibody (AchR\u2010Ab) levels in 21 MG patients after PP was analyzed.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Patients were divided into two groups: the favorable (<jats:italic>n<\/jats:italic>\u2009=\u200911) or unfavorable (<jats:italic>n<\/jats:italic>\u2009=\u200910) response groups around the median MG composite improvement rate (50 [29, 56]%) 2\u2009weeks after a PP course. In all patients, the IgG reduction rate before and after PP was higher in the favorable than the unfavorable response group. In AChR\u2010Ab\u2010positive patients, IgG and AChR\u2010Ab reduction rates were higher in the favorable than the unfavorable response group.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>IgG reduction rate is a predictor of symptom improvement in MG patients who underwent PP.<\/jats:p><\/jats:sec>","DOI":"10.1111\/1744-9987.14065","type":"journal-article","created":{"date-parts":[[2023,9,21]],"date-time":"2023-09-21T05:24:05Z","timestamp":1695273845000},"page":"131-140","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Serum immunoglobulin <scp>G<\/scp> level reduction is a predictor of short\u2010term improvement in patients with myasthenia gravis undergoing plasmapheresis"],"prefix":"10.1111","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8731-0663","authenticated-orcid":false,"given":"Shingo","family":"Konno","sequence":"first","affiliation":[{"name":"Department of Neurology Toho University Ohashi Medical Center  Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshiki","family":"Fujioka","sequence":"additional","affiliation":[{"name":"Department of Neurology Toho University Ohashi Medical Center  Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2023,9,20]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.74.8.1105"},{"key":"e_1_2_9_3_1","first-page":"47","volume-title":"Japanese clinical guidelines for myasthenia gravis and Lambert\u2010Eaton syndrome","author":"The Japanese Society of Neurology","year":"2022"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(17)30369-1"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(21)00159-9"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1002\/jca.21778"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0106757"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.55.1.16"},{"issue":"3","key":"e_1_2_9_9_1","first-page":"M597","article-title":"A simple and accurate method for prescribing plasma exchange","volume":"36","author":"Kaplan AA","year":"1990","journal-title":"ASAIO Trans"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1002\/mus.21185"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1002\/mus.25397"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2012.244"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1002\/mus.23398"},{"issue":"1","key":"e_1_2_9_14_1","first-page":"82","article-title":"Acetylcholine receptor antibody in myasthenia gravis: predominance of IgG subclasses 1 and 3","volume":"67","author":"R\u00f8dgaard A","year":"1987","journal-title":"Clin Exp Immunol"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.transci.2017.08.011"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2014.00520"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1002\/jca.21257"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM197711242972102"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1159\/000062987"},{"key":"e_1_2_9_20_1","unstructured":"NomuraK OjiS KubotaA TajimaT IsakiS IguchiT et al.Investigations on immunological diseases basis for pathophysiological analysis multiple sclerosis immunoadsorption (TR\u2010350) therapy has different removal ability depending on IgG subclass of autoantibodies. Research Group on Immunological Diseases Summary Report.200852\u20133. (In Japanese)."},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1002\/ana.410410615"},{"key":"e_1_2_9_22_1","first-page":"197","article-title":"Mechanisms of acetylcholine receptor loss from the neuromuscular junction","volume":"90","author":"Engel AG","year":"1982","journal-title":"Ciba Found Symp"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0404.1998.tb05968.x"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10072-014-2039-3"},{"key":"e_1_2_9_25_1","first-page":"426","volume-title":"Marino's The ICU Book International Edition","author":"Marino PL","year":"2013"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejcts.2007.05.018"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.1002\/jca.20129"}],"container-title":["Therapeutic Apheresis and Dialysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/1744-9987.14065","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,18]],"date-time":"2024-01-18T03:06:08Z","timestamp":1705547168000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/1744-9987.14065"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,20]]},"references-count":26,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,2]]}},"alternative-id":["10.1111\/1744-9987.14065"],"URL":"https:\/\/doi.org\/10.1111\/1744-9987.14065","archive":["Portico"],"relation":{},"ISSN":["1744-9979","1744-9987"],"issn-type":[{"value":"1744-9979","type":"print"},{"value":"1744-9987","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,20]]},"assertion":[{"value":"2022-09-06","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-09-04","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-09-20","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}